13
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Letter to the Editor: Low Dose Oral Idarubicin in Combination with Cyclophosphamide and Dexamethasone (CID) for Management of Melphalan-Prednisolone (MP) Resistant Myeloma

, , &
Pages 407-408 | Accepted 22 Aug 1998, Published online: 01 Jul 2009

References

  • Chisesi T, Capnist G, de Dominicis E, Dini E. A phase II study of idarubicin (4‐demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol 1988; 24: 681–4
  • Alberts A S, Falkson G, Rapoport B L, Uys A. A phase II study of idarubicin and prednisone in multiple myeloma. Tumori 1990; 76: 465–6, Samson D, Oral idarubicin with CCNU (lomustine) and dexatnethasone in the treatment of refractory or relapsed multiple myeloma, Research and Clinical Forums 1996, 18(3): 87–93
  • Cook G, Sharp R A, Tansey P, Franklin I M. A phase I/II trial of Z‐dex) oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Brit J Haematol 1996; 93: 9314
  • Samson D. Oral idarubicin with CCNU (lomustine) and dexamethasone in the treatment of refractory or relapsed multiple myeloma. Research and Clinical Forums 1996; 18(3)87–93
  • Samson D, Gaminara E, Newland A, Van de Pette J, Kearney J, McCarthy D, Joyner M, Aston L, Mitchell T, Hamon M, Barrett A J, Evans M. Infusion of vincristine and doxorubicin with oral dexamethasone as first‐line therapy for multiple myeloma. Lancet 1989; 2: 882–5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.